Search Results - "Szalony, James A"

Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model by Suleymanov, Osman D, Szalony, James A, Salyers, Anita K, LaChance, Rhonda M, Parlow, John J, South, Michael S, Wood, Rhonda S, Nicholson, Nancy S

“…This study was designed to evaluate the antithrombotic efficacy and bleeding propensity of a selective, small-molecule inhibitor of tissue factor/factor VIIa…”
Get more information

Administration of a small molecule tissue factor/Factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time by Szalony, James A, Suleymanov, Osman D, Salyers, Anita K, Panzer-Knodle, Susan G, Blom, Jason D, LaChance, Rhonda M, Case, Brenda L, Parlow, John J, South, Michael S, Wood, Rhonda S, Nicholson, Nancy S

“…Introduction: Pharmacological treatment of deep vein thrombosis (DVT) in the future may target inhibitors of specific procoagulant proteins. This study used a…”
Get full text

Pharmacological intervention at disparate sites in the coagulation cascade: Comparison of anti-thrombotic efficacy vs. bleeding propensity in a rat model of acute arterial thrombosis by SZALONY, James A, TAITE, Beatrice B, GIRARD, Thomas J, NICHOLSON, Nancy S, LACHANCE, Rhonda M

“…The Tissue Factor/Factor VIIa (TF/FVIIa) complex is an attractive target for pharmacological interruption of thrombin generation and hence blood coagulation,…”
Get full text

Assessment of bleeding propensity in non-human primates by combination of selective tissue factor/VIIa inhibition and aspirin compared to warfarin and aspirin treatment by Salyers, Anita K, Szalony, James A, Suleymanov, Osman D, Parlow, John J, Wood, Rhonda S, South, Michael S, Nicholson, Nancy S

“…This study in non-human primates was designed to evaluate the bleeding propensity of a selective, small molecule inhibitor of tissue factor (TF)/VIIa in…”
Get more information

Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist by Nicholson, Nancy S., Abood, Norman A., Panzer-Knodle, Susan G., Frederick, Leo G., Page, Jimmy D., Salyers, Anita K., Suleymanov, Osman D., Szalony, James A., Taite, Beatrice B., Anders, Robert J.

“…A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes, and restenosis after…”
Get full text

SC-54684A : an orally active inhibitor of platelet aggregation by NICHOLSON, N. S, PANZER-KNODLE, S. G, ENGLEMAN, V. W, HERIN, M, JACQMIN, P, FEIGEN, L. P, SALYERS, A. K, TAITE, B. B, SZALONY, J. A, HAAS, N. F, KING, L. W, ZABLOCKI, J. A, KELLER, B. T, BROSCHAT, K

“…Intravenous therapy has been shown to be beneficial in the prevention of acute platelet-associated thrombotic events. However, orally active agents would be…”
Get full text

Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A by SZALONY, J. A, HAAS, N. F, SALYERS, A. K, TAITE, B. B, NICHOLSON, N. S, MEHROTRA, D. V, FEIGEN, L. P

“…Platelet aggregation is important in thrombotic events, and platelets play a major role in the etiology of several cardiovascular diseases. Platelet…”
Get full text

Protective effect of oral xemilofiban in arterial thrombosis in dogs: Increased activity in combination with aspirin by FREDERICK, L. G, SULEYMANOV, O. D, SZALONY, J. A, TAITE, B. B, SALYERS, A. K, KING, L. W, FEIGEN, L. P, NICHOLSON, N. S

“…Inhibition of platelet aggregation by preventing the binding of fibrinogen to glycoprotein (GP) IIb/IIIa on activated platelets results in antithrombotic…”
Get full text

Assessment of platelet function assays by Nicholson, Nancy S., Panzer-Knodle, Susan G., Haas, Neal F., Taite, Beatrice B., Szalony, James A., Page, Jimmy D., Feigen, Larry P., Lansky, David M., Salyers, Anita K.

“…Optical aggregometry, traditionally used to assess platelet function, is highly dependent on sample preparation and technical procedure; as a result, data from…”
Get full text

Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists by Zablocki, Jeffery A, Rico, Joseph G, Garland, Robert B, Rogers, Thomas E, Williams, Kenneth, Schretzman, Lori A, Rao, Shashidhar A, Bovy, Philippe R, Tjoeng, Foe S

“…Our initial orally active fibrinogen receptor antagonist benzamidinopentanoyl (BAP) series which was discovered through truncation of our i.v. antiplatelet…”
Get full text

Protective effect of oral xemilofiban in arterial thrombosis in dogs: Incresed activity in combination with aspirin by Frederick, Leo G, Suleymanov, Osman D, Szalony, James A, Taite, Beatrice B

“…BACKGROUND: Inhibition of platelet aggregation by preventing the binding of fibrinogen to glycoprotein (GP) IIb/IIIa on activated platelets results in…”
Get full text